In the A549 tumor model, while only two mice in the traditional MSLN CAR-T group exhibited near-complete tumor clearance, all mice in the NKG2D/CD28& MSLN CAR-T group achieved full tumor clearance. This evidence concerns the gene CD28 and neoplasm.